Article preview from "The Gray Sheet" - February 7, 2011
Almost a year after signaling its intent to target more executives with misdemeanor prosecutions when their companies have broken the law, FDA has published its criteria for pursuing such cases.
Article preview from "The Gray Sheet" - February 7, 2011
Almost a year after signaling its intent to target more executives with misdemeanor prosecutions when their companies have broken the law, FDA has published its criteria for pursuing such cases.
The criteria, which make up a newly added section of the agency's "regulatory procedures manual," include a handful of factors that may drive FDA to recommend that federal attorneys go after individuals rather than just a corporation when Federal Food, Drug and Cosmetic Act violations are alleged.
Among the considerations: the individual's position and authority within a company; whether a violation is likely to have harmed the public; the obviousness of the violation; and more practical-minded considerations like "whether the proposed prosecution is a prudent use of agency resources."
To purchase this article online or get it FREE when you subscribe to "The Gray Sheet".
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512




.jpg)
.jpg)


Comments